Denali Therapeutics Inc.
DNLI- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001714899
In the last 90 days, Denali Therapeutics Inc. insiders filed 0 open-market purchases and 4 sales; 294 institutions reported holding it in 13F filings for Q2 2026, worth $4.00B in total; no superinvestor holds it.
13F holders, Q4 2022
Institutional positions in Denali Therapeutics Inc. as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 199
- −1 vs. Q3 2022
- Shares held
- 105.9M
- +13.5M (+14.6%) vs. Q3 2022
- Total value
- $2.94B
- +$108.6M (+3.8%) vs. Q3 2022
- New holders
- 27
- 86 more added
- Sold out
- 28
- 53 more reduced
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting DNLI on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 294 | $4.00B |
| Q1 2026 | 269 | $2.82B |
| Q4 2025 | 250 | $2.50B |
| Q3 2025 | 240 | $1.97B |
| Q2 2025 | 231 | $1.93B |
| Q1 2025 | 222 | $1.85B |
| Q4 2024 | 224 | $2.61B |
| Q3 2024 | 217 | $3.69B |
| Q2 2024 | 203 | $2.88B |
| Q1 2024 | 211 | $2.51B |
| Q4 2023 | 209 | $2.47B |
| Q3 2023 | 195 | $2.24B |
| Q2 2023 | 203 | $3.18B |
| Q1 2023 | 202 | $2.49B |
| Q4 2022 | 199 | $2.94B |
| Q3 2022 | 200 | $2.84B |
| Q2 2022 | 188 | $2.73B |
| Q1 2022 | 190 | $2.79B |
| Q4 2021 | 213 | $3.80B |
| Q3 2021 | 214 | $4.28B |
| Q2 2021 | 210 | $6.32B |
| Q1 2021 | 218 | $4.60B |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding Denali Therapeutics Inc.; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Castleark Management LLC | 0 | $0 | 0.00% | −127,460−100.0% | Sold out |
| Integral Health Asset Management, LLC | 0 | $0 | 0.00% | −115,000−100.0% | Sold out |
| Jump Financial, LLC | 0 | $0 | 0.00% | −102,152−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −77,628−100.0% | Sold out |
| Natixis | 0 | $0 | 0.00% | −69,030−100.0% | Sold out |
| Putnam Investments LLC | 0 | $0 | 0.00% | −64,044−100.0% | Sold out |
| Toronto Dominion Bank | 0 | $0 | 0.00% | −42,650−100.0% | Sold out |
| PDT Partners, LLC | 0 | $0 | 0.00% | −30,588−100.0% | Sold out |
| Jackson Creek Investment Advisors LLC | 0 | $0 | 0.00% | −27,381−100.0% | Sold out |
| Hillsdale Investment Management Inc. | 0 | $0 | 0.00% | −25,700−100.0% | Sold out |
| ExodusPoint Capital Management, LP | 0 | $0 | 0.00% | −23,434−100.0% | Sold out |
| AlphaCrest Capital Management LLC | 0 | $0 | 0.00% | −20,234−100.0% | Sold out |
| Duality Advisers, LP | 0 | $0 | 0.00% | −19,728−100.0% | Sold out |
| Arrowstreet Capital, Limited Partnership | 0 | $0 | 0.00% | −18,725−100.0% | Sold out |
| Fox Run Management, L.L.C. | 0 | $0 | 0.00% | −14,977−100.0% | Sold out |
| Delphia (USA) Inc. | 0 | $0 | 0.00% | −14,414−100.0% | Sold out |
| Corton Capital Inc. | 0 | $0 | 0.00% | −14,154−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −13,365−100.0% | Sold out |
| NinePointTwo Capital | 0 | $0 | 0.00% | −13,171−100.0% | Sold out |
| Levin Capital Strategies, L.P. | 0 | $0 | 0.00% | −9,500−100.0% | Sold out |
| Dynamic Technology Lab Private Ltd | 0 | $0 | 0.00% | −7,140−100.0% | Sold out |
| Point72 Hong Kong Ltd | 0 | $0 | 0.00% | −4,753−100.0% | Sold out |
| Quantbot Technologies LP | 0 | $0 | 0.00% | −3,700−100.0% | Sold out |
| Amundi | 0 | $0 | 0.00% | −3,017−100.0% | Sold out |
| Macquarie Group Ltd | 0 | $0 | 0.00% | −832−100.0% | Sold out |
| Capital Advisors, Ltd. LLC | 0 | $0 | 0.00% | −6−100.0% | Sold out |
| Parallel Advisors, LLC | 0 | $0 | 0.00% | −10−100.0% | Sold out |